| Compounds | Topics | Title | Date |
|---|---|---|---|
| CBD | epilepsy via model | The proposed multimodal mechanism of action of cannabidiol (CBD) in epilepsy: modulation of intracellular calcium and adenosine-mediated signaling | May 2019 |
|
Action Pathway: GPR55,TRPV1,ENT1 While the precise mechanisms by which CBD exerts its anticonvulsant properties in humans remain unknown, growing preclinical evidence suggests CBD reduces neuronal hyperexcitability through a unique multimodal mechanism of action. CBD antagonizes GPR55 at excitatory synapses, desensitizes TRPV1 channels, and inhibits adenosine reuptake. | |||
| CBD | epilepsy,anti-inflamatory,neuroprotective via review | Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders | May 2014 |
| The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G-protein-coupled receptor GPR55; the transient receptor potential of melastatin type 8 channel; the 5-HT1a receptor; the alpha-3 and alpha-1 glycine receptors; and the transient receptor potential of ankyrin type 1 channel. CBD has neuroprotective and anti-inflammatory effects. | |||
| Epidiolex,CBD | epilepsy via review | Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects | Feb 2019 |
| More recently, several randomized controlled and open label trials have studied the effects of Epidiolex, a 99% pure oral CBD extract, on patients with refractory epilepsy. This in turn has led to the FDA approval of and more recently, to the Drug Enforcement Administrations placement of Epidiolex into schedule V of the Controlled Substances Act (CSA) | |||
| Linalool | anxiety,insomnia,epilepsy in mice | Anxiolytic and sedative effects of extracts and essential oil from Citrus aurantium L. | Dec 2002 |
| The results obtained with EOP in the anxiety model, and with EOP, HF and DF in the sedation model, are in accord with the ethnopharmacological use of Citrus aurantium L., which could be useful in primary medical care, after toxicological investigation. | |||
| CBD,CBDV | epilepsy in vitro via experiment | Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. | Nov 2014 |
|
Action Pathway: TRPV1 However, TRPV1 was strongly phosphorylated (and hence likely sensitized) in Mg(2+)-free solution-treated hippocampal tissue, and both capsaicin and CBDV caused TRPV1 dephosphorylation, consistent with TRPV1 desensitization. We propose that CBDV effects on TRP channels should be studied further in different in vitro and in vivo models of epilepsy. | |||
| cannabis | epilepsy in human via trial (n=77) | CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. | Feb 2016 |
|
Ingestion Method: 1 to 20mg/kg/d, 20:1 CBD Positive CBD treatment yielded a significant positive effect on seizure load. Most of the children (66/74, 89%) reported reduction in seizure frequency | |||
| CBD | epilepsy via review | Cannabidiol and epilepsy: Rationale and therapeutic potential | May 2016 |
| In in vivo preclinical studies, CBD has shown significant anticonvulsant effects mainly in acute animal models of seizures, whereas restricted data exist in chronic models of epilepsy as well as in animal models of epileptogenesis. Likewise, clinical evidence seems to indicate that CBD is able to manage epilepsy both in adults and children affected by refractory seizures, with a favourable side effect profile. | |||
| Caryophyllene | epilepsy in mice via experiment | Pharmacological characterization of the cannabinoid receptor 2 agonist, beta--caryophyllene on seizure models in mice. | Apr 2018 |
|
Action Pathway: CB2 Our results suggest that the CB2 receptor agonists might be clinically useful as an adjunct treatment against seizure spread and status epilepticus and concomitant oxidative stress, neurotoxicity and cognitive impairments. | |||
| Epidiolex,CBD | epilepsy in humans via trial (n=45) | Open-label use of highly purified CBD (Epidiolex(R)) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. | Sep 2018 |
| This open-label drug trial provides class III evidence for the long-term safety and efficacy of CBD administration in patients with treatment-resistant epilepsy (TRE) associated with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. | |||
| Epidiolex,CBD | epilepsy via review | Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. | Jun 2019 |
| This is the first cannabis-derived medication with approval from the US Food and Drug Administration. This CBD formulation significantly reduces seizures as an adjunct to standard antiepileptic therapies in patients >=2 years old with DS and LGS and is well tolerated. | |||
| CBD | epilepsy in humans via placebo trial (n=225) | Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy. | Apr 2019 |
|
Ingestion Method: 10 - 20 mg/kg Positive The median percentage reduction from baseline in drop seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group, 37.2% in the 10-mg cannabidiol group, and 17.2% in the placebo group ( P = .005 for the 20-mg cannabidiol group vs placebo group, and P = .002 for the 10-mg cannabidiol group vs placebo group) | |||
| CBD | epilepsy in vitro | Investigating the Therapeutic Mechanism of Cannabidiol in a Human Induced Pluripotent Stem Call (iPSC)-Based Cellular Model of Dravet Syndrome. | Jun 2019 |
| Our findings suggest a cell type-dependent mechanism for the therapeutic action of CBD in Dravet syndrome that is independent of sodium channel activity. | |||